Associated Papers
Common epidermal growth factor receptor mutations in north Indian patients with non-small cell lung carcinoma: evidence from real-time polymerase chain reaction.
Behera R et al.
Monaldi Archives for Chest Disease = Archivio Monaldi Per Le Malattie Del Torace, 2025
Biomarker testing in lung cancer: from bench to bedside.
Batra U et al.
Oncology Reviews, 2024
FBXL2 counteracts Grp94 to destabilize EGFR and inhibit EGFR-driven NSCLC growth.
Niu M et al.
Nature Communications, 2021
Integrated Omics Analysis of Non-Small-Cell Lung Cancer Cells Harboring the EGFR C797S Mutation Reveals the Potential of AXL as a Novel Therapeutic Target in TKI-Resistant Lung Cancer.
Wang TH et al.
Cancers, 2020
Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms.
Proto C et al.
Tumori, 2017
Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer.
Barnes TA et al.
Frontiers in Oncology, 2017
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.
Chabon JJ et al.
Nature Communications, 2016
EGFR Exon 18 Mutations in East Asian Patients with Lung Adenocarcinomas: A Comprehensive Investigation of Prevalence, Clinicopathologic Characteristics and Prognosis.
Cheng C et al.
Scientific Reports, 2015
Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.
Zhang Y et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2012
Select a paper to view details